Cita APA (7a ed.)

J, S., M, B., BA, S., J, L., A, O., & P, K. (2021). Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca. Dove Medical Press.

Cita Chicago Style (17a ed.)

J, Sheppard, Bergmann M, Schechter BA, Luchs J, Ogundele A, y Karpecki P. Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca. Dove Medical Press, 2021.

Cita MLA (8a ed.)

J, Sheppard, et al. Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca. Dove Medical Press, 2021.